quinacrine has been researched along with Cancer of Cervix in 11 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using 5-Fluouracil-resistant cervical cancer stem cells (PEMT-5FU-R-MC) and different NECTIN-4 domain-specific constructs, different domains of NECTIN-4 were over-expressed in PEMT-5FU-R-MC cells." | 1.56 | Nanoformulated quinacrine regulates NECTIN-4 domain specific functions in cervical cancer stem cells. ( Chatterjee, S; Kundu, CN, 2020) |
| "Cervical cancer is a major cause of cancer-related death in women world-wide." | 1.51 | Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation. ( Das, S; Kundu, CN; Narayan, S; Nayak, A; Nayak, D; Sethy, C, 2019) |
| "NQC exhibited more toxicity in cervical cancer cells and its CSCs than QC." | 1.43 | Nanoquinacrine induced apoptosis in cervical cancer stem cells through the inhibition of hedgehog-GLI1 cascade: Role of GLI-1. ( Bharatam, PV; Das, D; Kundu, C; Nayak, A; Satapathy, SR; Siddharth, S; Tripathi, N, 2016) |
| "Ten cases of cervical cancer were observed, compared with 12." | 1.36 | Cancer risk after sterilization with transcervical quinacrine: updated findings from a Chilean cohort. ( Guzmán, SC; Guzman-Serani, R; Hubacher, D; Sokal, DC; Trujillo, V; Wheeless, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Chatterjee, S | 1 |
| Kundu, CN | 2 |
| Nayak, A | 2 |
| Das, S | 1 |
| Nayak, D | 1 |
| Sethy, C | 1 |
| Narayan, S | 1 |
| Satapathy, SR | 1 |
| Das, D | 1 |
| Siddharth, S | 1 |
| Tripathi, N | 1 |
| Bharatam, PV | 1 |
| Kundu, C | 1 |
| Sokal, DC | 3 |
| Trujillo, V | 1 |
| Guzmán, SC | 1 |
| Guzman-Serani, R | 1 |
| Wheeless, A | 1 |
| Hubacher, D | 1 |
| Vach, TH | 1 |
| Nanda, K | 1 |
| McCann, MF | 1 |
| Weiner, DH | 1 |
| Drobnes, C | 1 |
| Rochanawutanon, M | 1 |
| Duc, NB | 1 |
| Loan, ND | 1 |
| Dabancens, A | 2 |
| Pruyas, M | 2 |
| Rivera, M | 2 |
| Zipper, J | 2 |
| Sokal, D | 1 |
| Fasanmade, AA | 1 |
| Owuor, ED | 1 |
| Ee, RP | 1 |
| Qato, D | 1 |
| Heller, M | 1 |
| Kong, AN | 1 |
| Mutch, DG | 1 |
| Powell, CB | 1 |
| Kao, MS | 1 |
| Collins, JL | 1 |
| Lee, M | 1 |
| Boyes, DA | 1 |
| Montanari, GD | 1 |
| Grismondi, GL | 1 |
1 trial available for quinacrine and Cancer of Cervix
| Article | Year |
|---|---|
[Standardized rates of incidence and prevalence of cervical preclinical pathology in 1,061 women sterilized with intrauterine quinacrine].
Topics: Adolescent; Adult; Female; Humans; Instillation, Drug; Middle Aged; Quinacrine; Sterilization, Repro | 1994 |
10 other studies available for quinacrine and Cancer of Cervix
| Article | Year |
|---|---|
Nanoformulated quinacrine regulates NECTIN-4 domain specific functions in cervical cancer stem cells.
Topics: Active Transport, Cell Nucleus; alpha Karyopherins; Antineoplastic Agents; Cell Adhesion Molecules; | 2020 |
Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation.
Topics: ADAM17 Protein; Cell Adhesion Molecules; Cell Line, Tumor; Cell Nucleus; DNA Repair; Down-Regulation | 2019 |
Nanoquinacrine induced apoptosis in cervical cancer stem cells through the inhibition of hedgehog-GLI1 cascade: Role of GLI-1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Femal | 2016 |
Cancer risk after sterilization with transcervical quinacrine: updated findings from a Chilean cohort.
Topics: Chile; Cohort Studies; Databases, Factual; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; | 2010 |
Quinacrine sterilization and gynecologic cancers: a case-control study in northern Vietnam.
Topics: Age Factors; Case-Control Studies; Confidence Intervals; Female; Genital Neoplasms, Female; Humans; | 2010 |
Prevalence and standardized incidence rates of preclinical cervical pathology among 1,061 women sterilized with transcervical quinacrine hydrochloride pellets.
Topics: Adolescent; Adult; Aged; Carcinoma in Situ; Female; Follow-Up Studies; Humans; Incidence; Middle Age | 1995 |
Quinacrine induces cytochrome c-dependent apoptotic signaling in human cervical carcinoma cells.
Topics: Antimalarials; Apoptosis; Blotting, Western; Caspase 8; Caspase 9; Caspases; Cytochrome c Group; Dru | 2001 |
Resistance to cytolysis by tumor necrosis factor alpha in malignant gynecological cell lines is associated with the expression of protein(s) that prevent the activation of phospholipase A2 by tumor necrosis factor alpha.
Topics: Animals; Arachidonic Acid; Cell Line; Cell Survival; Drug Resistance; Emetine; Female; Humans; Mice; | 1992 |
The use of quinacrine hydrochloride for the control of malignant serous effusions.
Topics: Ascites; Female; Humans; Injections, Intraperitoneal; Ovarian Neoplasms; Quinacrine; Remission, Spon | 1971 |
[Intravital fluorescence of carcinoma of the cervix uteri induced by quinacrine].
Topics: Adult; Aged; Colposcopy; Female; Fluorescence; Humans; Middle Aged; Quinacrine; Uterine Cervical Neo | 1970 |